Revenue - Additional Information (Details) dose in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2023 USD ($)	Jun. 30, 2023 USD ($) dose	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) dose installment	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Nov. 18, 2022 dose	Dec. 31, 2021 USD ($)
Revenue Recognition
Billed contracts receivable		$ 334,400,000		$ 334,400,000		$ 53,800,000
Unbilled contracts receivable		60,500,000		60,500,000		28,600,000
Amount of transaction price not yet satisfied		2,000,000,000		2,000,000,000
Deferred revenue		907,410,000	$ 1,516,147,000	907,410,000	$ 1,516,147,000	549,551,000		$ 1,595,472,000
Reduction in product sales				64,700,000
Revenues		424,426,000	185,925,000	505,377,000	889,896,000
Sales-Based Royalties
Revenue Recognition
Revenues		$ 0	1,700,000	$ 0	9,200,000
Sales-Based Royalties | JAPAN
Revenue Recognition
Revenues			$ 20,000,000		$ 20,000,000
Gavi Advance Purchase Agreement SIIPL
Revenue Recognition
Deferred revenue								$ 350,000,000
Number of doses to be distributed | dose		1,100		1,100
Remaining performance obligation, variable consideration amount						$ 350,000,000
Gavi Advance Purchase Agreement- COVAX Facility
Revenue Recognition
Number of doses to be distributed | dose							350
Purchase agreement, number of vaccine doses | dose							2
Collaboration agreement upfront payment amount		$ 696,400,000		$ 696,400,000
Canada APA
Revenue Recognition
Collaboration agreement upfront payment amount		$ 100,400,000		100,400,000
Total payment amount				$ 349,600,000
Number of equal installments | installment				2
Obligation to deliver, terms				15 years
Installment charges				$ 174,800,000
Percent of remaining amount to be paid		100.00%		100.00%
Escrow to sales hold				$ 20,000,000
Canada APA | Subsequent Events
Revenue Recognition
Installment charges	$ 174,800,000
US Government Partnership
Revenue Recognition
Contingent upon meeting certain milestones amount		$ 60,000,000		60,000,000
Grant consideration, amount development and regulatory milestones		1,500,000		1,500,000
Grant consideration, amount subject to third parties		$ 48,000,000		48,000,000
Grant revenue reduction				$ 29,000,000